Details

Autor(en) / Beteiligte

• Agrawal, Rajiv K
• Alhasso, Abdulla
• Barrett-Lee, Peter J
• Bliss, Judith M
• Bliss, Peter
• Bloomfield, David
• Bowen, Joanna
• Brunt, A Murray
• Donovan, Ellen
• Emson, Marie
• Goodman, Andrew
• Harnett, Adrian
• Haviland, Joanne S
• Kaggwa, Ronald
• Morden, James P
• Robinson, Anne
• Simmons, Sandra
• Stewart, Alan
• Sydenham, Mark A
• Syndikus, Isabel
• Tremlett, Jean
• Tsang, Yat
• Wheatley, Duncan
• Venables, Karen
• Yarnold, John R

Titel

First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015)

Ist Teil von

• Radiotherapy and oncology, 2011-07, Vol.100 (1), p.93-100

Ort / Verlag

Ireland: Elsevier Ireland Ltd

Erscheinungsjahr

2011

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Abstract Background and purpose Randomised trials testing 15- or 16-fraction regimens of adjuvant radiotherapy in women with early breast cancer have reported favourable outcomes compared with standard fractionation. To evaluate hypofractionation further, two 5-fraction schedules delivering 1 fraction per week have been tested against a 25-fraction regimen. Materials and methods Women aged ⩾50 years with node negative early breast cancer were randomly assigned after microscopic complete tumour resection to 50 Gy in 25 fractions versus 28.5 or 30 Gy in 5 once-weekly fractions of 5.7 or 6.0 Gy, respectively, to the whole breast. The primary endpoint was 2-year change in photographic breast appearance. Results Nine hundred and fifteen women were recruited from 2004 to 2007. Seven hundred and twenty-nine patients had 2-year photographic assessments. Risk ratios for mild/marked change were 1.70 (95% CI 1.26–2.29, p < 0.001) for 30 Gy and 1.15 (0.82–1.60, p = 0.489) for 28.5 Gy versus 50 Gy. Three-year rates of physician-assessed moderate/marked adverse effects in the breast were 17.3% (13.3–22.3%, p < 0.001) for 30 Gy and 11.1% (7.9–15.6%, p = 0.18) for 28.5 Gy compared with 9.5% (6.5–13.7%) after 50 Gy. With a median follow-up in survivors of 37.3 months, 2 local tumour relapses and 23 deaths have occurred. Conclusions At 3 years median follow-up, 28.5 Gy in 5 fractions is comparable to 50 Gy in 25 fractions, and significantly milder than 30 Gy in 5 fractions, in terms of adverse effects in the breast.